Ankesh Kumar Jaiswal
Scientist-C |
Decision Unit 2: Disease Biology
Professor |
Academy of Scientific and Innovative Research
Ankesh Kumar Jaiswal's lab focuses on developing novel next-generation Chimeric Antigen Receptors (CARs)-based immune cell therapies for the treatment of leukaemia and solid tumours, aiming to enhance the therapeutic efficacy, persistence, and safety of CAR-engineered immune cell therapies (CAR-T, CAR-NK, etc.). Novel therapies aim to provide superior and long-term remission for cancer patients. His laboratory is also interested in in vivo immune cell engineering to generate CAR therapies within the patients and bypass the ex vivo manufacturing.
Current Focus Areas
- Next-generation Chimeric Antigen Receptor T cells for B cell malignancy
- Armored Chimeric Antigen Receptor T cell for solid tumours
- Chimeric Antigen Receptor natural killer cell (CAR-NK) cell platform for treatment of cancers
Ankesh's previous studies involved the development of India's 1st Chimeric Antigen Receptor T cell therapy targeting the CD19 antigen on cancerous B cells. The study also revealed that prior therapies affect CAR-T cells product manufacturing, quality and clinical responses, suggesting early enrolment in CAR therapy treatment will have a superior response.
Selected Publications
- Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study. Jain H, Karulkar A, Kalra D, Ravikumar S, Shah S, Firfiray A, Pendhari J, Jaiswal AK, Khan A, Purwar R, et al.; CAR-T clinical trial group. Lancet Haematology. 2025 Apr;12(4):e282–e293.
- Excellent safety profile of a low-cost novel humanized CD19 CAR T-cell therapy, actalycabtagene autoleucel: potential impact on access and feasibility. Karulkar A, Jaiswal AK, Khan A, Kalra D, Ravikumar S, Ghandade N, Patil R, Shah S, Firfiray A, Pendhari J, Patil R. Blood. 2023 Nov 2;142:257.
- Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/refractory pediatric B-acute lymphoblastic leukemia — an open-label single-arm phase-I/Ib study. Narula G, Keerthivasagam S, Jain H, Punatar S, Chichra A, Dhamne C, Tembhare P, Subramanian PG, Patkar N, Poojary M, Gokarn A, Jaiswal AK. Blood Cancer Journal. 2025 Apr 24;15(1):75.
- Robust antitumor activity and low cytokine production by novel humanized anti-CD19 CAR T cells. Dwivedi A, Karulkar A, Ghosh S, Srinivasan S, Kumbhar BV, Jaiswal AK, Kizhakeyil A, Asija S, Rafiq A, Kumar S, Nisar A. Molecular Cancer Therapeutics. 2021 May 1;20(5):846–58.